<DOC>
	<DOCNO>NCT00698243</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) establish recommend phase 2 dose oral OSI-027 administer via 3 schedule , namely , intermittent , weekly , continuous patient advance solid tumor lymphoma , namely , intermittent , weekly , continuous .</brief_summary>
	<brief_title>Study Oral OSI-027 Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>The study open Schedule 1 ( S1 , intermittent ) initiation Schedule 2 ( S2 , weekly ) Schedule 3 ( S3 , continuous ) , may occur parallel observation clinically significant relate dose limit toxicity ( DLT ) S1 schedule . Dosing initiated Day 1 intermittent weekly dose continue 21 day ( 1 Treatment Period ) . Expansion Dose Escalation Cohorts may occur S1 S2 recommend phase 2 dose level ( ) Biomarker Expansion Cohort may open S1 and/or S2 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Histologically cytologically document malignancy ( solid tumor lymphoma ) Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) ≤ 2 Predicted life expectancy least 3 month Adequate hematopoietic hepatic function , normal renal function Fasting glucose &lt; 7mmol/L baseline Left ventricular ejection fracture ( LVEF ) Multiple gated acquisition scan ( MUGA ) ≥ 60 % Practice effective contraceptive measure throughout study Verbal write informed consent Prior therapy : Chemotherapy , minimum 3 week recover treatmentrelated toxicity ( except alopecia , grade 1 neurotoxicity ) prior registration Hormonal , discontinue prior registration Radiation , minimum 21 day recover toxic effect prior registration Surgery , provide wound heal occurred History significant cardiac disease unless well control Discontinuation prior therapy due cardiac toxicity Active uncontrolled infection Serious illness medical condition could interfere study participation History psychiatric condition might impair understand compliance Documented history diabetes mellitus Pregnant breastfeeding female Unstable symptomatic brain metastasis , require steroid require radiation last 28 day Chronic systemic steroid use cancer related condition History allergic reaction Patients cataract expect undergo surgery within 6 month registration Use drug cause QT interval prolongation within 14 day prior dose Patients clinically significant electrolyte imbalance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>OSI-027</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Lymphoma</keyword>
</DOC>